BOULDER, Colo., April 5, 2006 /PRNewswire via COMTEX/ -- Sciona, Inc., a world leader in the area of personalized genetics, announced today that it has successfully closed a $6.5 million private round raised from its current venture investors. The funds will be used to continue the development of Sciona's nutra-genetics business. The financing participants included DSM Venturing, Prelude Trust, Burrill and Company, BioVentures Inc., BASF Venture Capital, and Semola Limited.
Sciona has developed and is marketing Cellf(TM), a proprietary DNA screen for critical gene variants that, when correlated to an individual's diet, provides specific personalized recommendations for food or nutrient intake to enhance health and wellness. Sciona's genetic personalization technology provides individual access to non-medical genetic data in absolute privacy.
Chris Martin, Sciona founder and chairman said, "Sciona believes that breakthroughs in the collection and analysis of genetic data will allow us to meet the growing demand of a more health conscious population desiring customized, direct access to personalized health information. The proprietary Cellf(TM) kit is the leading product supplying non-medical genetic data directly to consumers."
The Cellf(TM) testing procedure uses cheek-swab technology that allows individuals to collect their own DNA samples in the privacy of their home. Because Sciona provides its services directly to individuals, it is able to assure absolute privacy for the genetic data and its interpretation, giving the consumer total control of the decision of whom to share their data with.
Sciona provides personalized health and nutrition recommendations based on an individual's diet, lifestyle and unique genetic profile. The company has created a powerful set of tools enabling consumers and consumer product companies to harness the scientific information derived from the Human Genome Project. For additional information, visit www.sciona.com.